HN2007000536A - Formas cristalinas - Google Patents

Formas cristalinas

Info

Publication number
HN2007000536A
HN2007000536A HN2007000536A HN2007000536A HN2007000536A HN 2007000536 A HN2007000536 A HN 2007000536A HN 2007000536 A HN2007000536 A HN 2007000536A HN 2007000536 A HN2007000536 A HN 2007000536A HN 2007000536 A HN2007000536 A HN 2007000536A
Authority
HN
Honduras
Prior art keywords
crystal forms
tetrafluofenoxi
tercbutilfenil
oxopentanoico
alamini
Prior art date
Application number
HN2007000536A
Other languages
English (en)
Inventor
Dimmock Stuart
Hagen Eric
Hanko Jason
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN2007000536A publication Critical patent/HN2007000536A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A FORMAS CRISTALINAS DEL ACIDO (3S)- {N-(N -(2-TERCBUTILFENIL) OXAMIL) ALAMINI} AMINO-5-(2, 3, 5, 6-TETRAFLUOFENOXI)-4-OXOPENTANOICO.
HN2007000536A 2006-12-06 2007-12-04 Formas cristalinas HN2007000536A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86874806P 2006-12-06 2006-12-06

Publications (1)

Publication Number Publication Date
HN2007000536A true HN2007000536A (es) 2011-01-17

Family

ID=39205161

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2007000536A HN2007000536A (es) 2006-12-06 2007-12-04 Formas cristalinas

Country Status (23)

Country Link
US (1) US7692038B2 (es)
EP (1) EP2091910B1 (es)
JP (1) JP5495787B2 (es)
KR (1) KR101125932B1 (es)
CN (3) CN103923169B (es)
AR (1) AR064809A1 (es)
AU (1) AU2007330478B2 (es)
CA (1) CA2669849C (es)
CL (1) CL2007003491A1 (es)
DK (1) DK2091910T3 (es)
ES (1) ES2524021T3 (es)
HK (3) HK1138567A1 (es)
HN (1) HN2007000536A (es)
IL (1) IL198732A (es)
MX (1) MX2009006055A (es)
NO (1) NO338908B1 (es)
PA (1) PA8759501A1 (es)
PE (1) PE20081251A1 (es)
PL (1) PL2091910T3 (es)
PT (1) PT2091910E (es)
TW (1) TWI345466B (es)
UY (1) UY30758A1 (es)
WO (1) WO2008068615A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4166558A1 (en) * 2010-02-12 2023-04-19 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one
CN103113405B (zh) * 2012-10-17 2016-03-02 上海日馨生物科技有限公司 苯磷硫胺多晶型体、制备方法及其应用
JP6564796B2 (ja) * 2014-03-14 2019-08-21 アジオス ファーマシューティカルズ， インコーポレイテッド 治療活性化合物の医薬組成物
CN106470679A (zh) 2014-05-12 2017-03-01 科内图斯医药公司 用半胱天冬酶抑制剂治疗慢性肝脏疾病并发症
BR112017003421B1 (pt) * 2014-09-08 2023-10-10 Pfizer Inc Formas sólidas cristalinas de 6-carbóxi-2-(3,5-dicloro-fenil)- benzoxazol e composição farmacêutica
CA2975048C (en) * 2015-01-30 2024-01-02 Biomed Valley Discoveries, Inc. Crystalline forms of c21h22ci2n4o2
WO2016144830A1 (en) 2015-03-06 2016-09-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
CN105017061B (zh) * 2015-07-07 2017-03-29 苏州富士莱医药股份有限公司 一种恩利卡生的合成方法
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
KR20180101418A (ko) 2015-12-31 2018-09-12 코나터스 파마슈티칼스, 인크. 간 질환의 치료에서의 카스파제 억제제의 사용 방법
CN109789119A (zh) 2016-10-05 2019-05-21 诺华股份有限公司 用于治疗或预防纤维化、硬化疾病或障碍的含fxr激动剂的复合组合物
US11434212B2 (en) 2017-01-23 2022-09-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bicyclic compound as a caspase inhibitor
JP2019514862A (ja) * 2017-03-23 2019-06-06 ノバルティス アーゲー （ｓ）−２−（ジフェニルアセチル）−１，２，３，４−テトラヒドロ−６−メトキシ−５−（フェニルメトキシ）−３−イソキノリンカルボン酸ナトリウムの無水結晶形
AU2018246255B2 (en) * 2017-03-30 2021-07-08 Merck Patent Gmbh Crystalline form of (s)-(2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl)-(6-methoxy-pyridazin-3-yl)-methanol
AR114251A1 (es) * 2018-02-13 2020-08-12 Syngenta Participations Ag Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida
EP3814327A1 (en) 2018-06-29 2021-05-05 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
SG11202109700PA (en) 2019-03-07 2021-10-28 Conatus Pharmaceuticals Inc Caspase inhibitors and methods of use thereof
CN111351780A (zh) * 2019-12-29 2020-06-30 中船重工（邯郸）派瑞特种气体有限公司 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE149483T1 (de) * 1991-07-30 1997-03-15 Ajinomoto Kk Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
EP0625504B1 (de) * 1993-05-12 1997-08-27 HEUMANN PHARMA GmbH Stabile und kristalline Form von Bezafibrat
US7053056B2 (en) * 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) * 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
CA2469882C (en) * 2001-12-11 2009-09-29 Kazuo Orita Novel stable crystals of substituted phenylpropionic acid derivative and process for producing the same
AU2006267976B2 (en) * 2005-07-11 2009-12-24 Pfizer Limited New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis

Also Published As

Publication number Publication date
CN103951583B (zh) 2016-01-06
UY30758A1 (es) 2008-07-31
CN101573328B (zh) 2014-04-02
CN103951583A (zh) 2014-07-30
PE20081251A1 (es) 2008-09-17
JP5495787B2 (ja) 2014-05-21
HK1200440A1 (zh) 2015-08-07
ES2524021T3 (es) 2014-12-03
DK2091910T3 (en) 2014-12-01
AU2007330478A1 (en) 2008-06-12
CN103923169B (zh) 2017-05-24
CA2669849C (en) 2012-01-31
CN103923169A (zh) 2014-07-16
JP2010511689A (ja) 2010-04-15
HK1138567A1 (en) 2010-08-27
US20080249031A1 (en) 2008-10-09
PT2091910E (pt) 2014-11-18
CN101573328A (zh) 2009-11-04
EP2091910A1 (en) 2009-08-26
IL198732A (en) 2014-02-27
AU2007330478B2 (en) 2011-09-08
TW200833319A (en) 2008-08-16
TWI345466B (en) 2011-07-21
WO2008068615A1 (en) 2008-06-12
MX2009006055A (es) 2009-06-16
WO2008068615A8 (en) 2009-05-28
HK1199885A1 (en) 2015-07-24
KR20090080113A (ko) 2009-07-23
EP2091910B1 (en) 2014-08-20
NO20091892L (no) 2009-06-17
AR064809A1 (es) 2009-04-29
CL2007003491A1 (es) 2008-06-20
CA2669849A1 (en) 2008-06-12
IL198732A0 (en) 2010-02-17
PL2091910T3 (pl) 2015-02-27
PA8759501A1 (es) 2009-04-23
NO338908B1 (no) 2016-10-31
US7692038B2 (en) 2010-04-06
KR101125932B1 (ko) 2012-03-22

Similar Documents

Publication Publication Date Title
HN2007000536A (es) Formas cristalinas
GT200600315A (es) Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
UY30639A1 (es) Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones
CR10157A (es) Compuestos químicos
CR9369A (es) Compuestos de peridil acido acetico
CR7680A (es) Un nuevo proceso para la sintesis de agomelatina
EA200801959A1 (ru) Высокоразветвленный полипропилен
CR11161A (es) Procesos para la produccion de pirazoles
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
UA107791C2 (en) Pesticidal compositions
TW200745028A (en) Novel sulphonylpyrroles
TW200745027A (en) Novel sulphonylpyrroles
RS54485B1 (en) C7-FLUORO SUBSTITUTED TETRACYCLINE UNITS
MX2009013276A (es) Compuestos anti-inflamatorios de ciclobutenodiona sustituida.
CY1118173T1 (el) 5-[(3,3,3-τριφθορο-2-υδροξυ-1-αρυλπροπυλ)αμινο]-1h-κινολιν-2-ονες, μια διεργασια για την παραγωγη τους και η χρηση τους ως αντι-φλεγμονωδων παραγοντων
DE502006005053D1 (de) Spritzbare akustikmassen
AR058253A1 (es) Procedimiento para la preparacion de ferri-succinilcaseina
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
TW200640886A (en) Crystalline forms of linezolid intermediate
UA107592C2 (uk) Композиція для боротьби з захворюваннями рослин і її застосування
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины
AR064658A1 (es) Proceso para preparar duloxetina y sus compuestos relacionados, asi como tambien intermediarios utiles en la misma
CY1116596T1 (el) Αλατα ισοφωσφοραμιδικης μουσταρδας και αναλογα αυτων
EA200702290A1 (ru) Мотилидные соединения